Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 4;10:4135–4144. doi: 10.2147/CMAR.S176575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Three-year RFS rate of the four patient cohorts. (A) Patients with pre- and post-op CTCs− (n=18), pre-op CTCs−, but post-op CTCs+ (n=11), pre-op CTCs+, but post-op CTCs− (n=57), and pre- and post-op CTCs+ (n=52). (B) Hazard functions for disease recurrence of different pre- and post-CTCs status.

Note: ^a Pre- and post-op CTCs+ vs pre- and post-op CTCs−, P=0.019; pre- and post-op CTCs+ vs pre-op CTCs−, but post-op CTCs+, P=0.220; pre- and post-op CTCs+ vs pre-op CTCs+, but post-op CTCs−, P=0.006.

Abbreviations: CTCs, circulating tumor cells; Post-op, post-operative; Pre-op, pre-operative; RFS, recurrence-free survival.